Provided by Tiger Trade Technology Pte. Ltd.

Heron Therapeutics

1.17
+0.01501.30%
Volume:186.55K
Turnover:215.77K
Market Cap:213.20M
PE:-13.55
High:1.18
Open:1.16
Low:1.15
Close:1.15
52wk High:2.68
52wk Low:0.9999
Shares:183.00M
Float Shares:153.00M
Volume Ratio:0.75
T/O Rate:0.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.0860
EPS(LYR):-0.0891
ROE:-2408.88%
ROA:0.42%
PB:30.36
PE(LYR):-13.08

Loading ...

Heron Therapeutics Inc. to Report Q4 and Full Year 2025 Results

Reuters
·
Yesterday

Heron Therapeutics: Undervalued Growth Story Driven by Zynrelef and Aponvie Momentum

TIPRANKS
·
Jan 10

Heron Therapeutics Price Target Maintained With a $6.00/Share by HC Wainwright & Co.

Dow Jones
·
Jan 10

Heron Therapeutics: ZYNRELEF-Led Commercial Inflection and Undemanding Valuation Support Buy Rating and $6 Target

TIPRANKS
·
Jan 10

BRIEF-Heron Therapeutics Announces Preliminary, Unaudited Q4 Results

Reuters
·
Jan 09

Heron Therapeutics sees Q4 revenue $40.5M, consensus $39.83M

TIPRANKS
·
Jan 09

Heron Therapeutics Reports Preliminary Q4 2025 Net Revenue of $40.5 Million

Reuters
·
Jan 09

Heron Therapeutics Inc - Reports Q4 2025 Net Revenue of $40.5 Mln

THOMSON REUTERS
·
Jan 09

Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; Zynrelef® Largest Contributor to Q4 Growth

THOMSON REUTERS
·
Jan 09

BRIEF-Heron Therapeutics Announces Inclusion Of Aponvie (Aprepitant)

Reuters
·
Dec 04, 2025

Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)

GlobeNewswire
·
Dec 04, 2025

Heron Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Director Thomas Cusack

Reuters
·
Nov 07, 2025

Heron Therapeutics’ Earnings Call: Growth Amid Challenges

TIPRANKS
·
Nov 05, 2025

Heron Therapeutics price target lowered to $5 from $6 at Jefferies

TIPRANKS
·
Nov 05, 2025

Heron Therapeutics: Buy Rating Affirmed Amid Promising Product Developments and Underappreciated Market Potential

TIPRANKS
·
Nov 05, 2025

Promising Growth and Strategic Initiatives Justify Buy Rating for Heron Therapeutics

TIPRANKS
·
Nov 05, 2025

UPDATE: Heron Therapeutics Q3 Adj. EPS $(0.04) Misses $(0.01) Estimate, Sales $38.213M Miss $39.031M Estimate

Benzinga
·
Nov 04, 2025

Heron Therapeutics reports Q3 2025 net revenue of $38.2 million

Reuters
·
Nov 04, 2025

Heron Therapeutics: Reaffirmed 2025 Net Revenue Guidance

THOMSON REUTERS
·
Nov 04, 2025

Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress

THOMSON REUTERS
·
Nov 04, 2025